Sawai Aims To Overcome US Slide
Japanese Firm Still Optimistic On Meeting Full-Year Forecasts
Sawai says it is still on track to meet its financial targets for the current financial year, despite a slump in US sales and profits.
You may also be interested in...
Sawai believes the Zembrace and Tosymra sumatriptan brands acquired by its US operation Upsher-Smith could within the next three years bring in more than $50m in annual sales.
In an exclusive interview, the president of Japan’s largest generics company relates his strategy for success, including internal expertise in intellectual property challenges and staying away from biosimilars. US acquisition Upsher-Smith will meanwhile provide the foundation for overseas growth.
Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.